Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001885751 | SCV002143336 | uncertain significance | not provided | 2023-08-30 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 739 of the TONSL protein (p.Ser739Cys). This variant is present in population databases (rs544190218, gnomAD 0.04%). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt TONSL protein function. ClinVar contains an entry for this variant (Variation ID: 1376170). This variant has not been reported in the literature in individuals affected with TONSL-related conditions. |
Ambry Genetics | RCV002552766 | SCV003755004 | uncertain significance | Inborn genetic diseases | 2021-07-20 | criteria provided, single submitter | clinical testing | The c.2215A>T (p.S739C) alteration is located in exon 17 (coding exon 17) of the TONSL gene. This alteration results from a A to T substitution at nucleotide position 2215, causing the serine (S) at amino acid position 739 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |